Sangamo showcases progress in our pre-clinical programs at ASGCT.

Click here to view

Zinc Finger Nuclease

Resolution of hepatic fibrosis after zinc-finger nuclease-mediated gene editing in the PiZ mouse model of human alpha-1-antitrypsin deficiency liver disease
March 7th, 2023
First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B
November 1st, 2022
Highly Efficient Gene Editing of Cystic Fibrosis Patient-derived Airway Basal Cells Results in Functional CFTR Correction
May 7th, 2020
Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets
May 7th, 2020
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1
May 7th, 2020
Enhancing gene editing specificity by attenuating DNA cleavage kinetics
December 6th, 2019
Diversifying the structure of zinc finger nucleases for high-precision genome editing
December 6th, 2019
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma
August 24th, 2018